Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Eisai Inc.
Janssen Research & Development, LLC
Astellas Pharma Inc
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC
Astellas Pharma Inc
Merck Sharp & Dohme LLC
Merck Sharp & Dohme LLC